Ticker > Company >

Accretion Pharma. share price

Accretion Pharmaceuticals Ltd.

NSE: ACCPL SECTOR: Pharmaceuticals & Drugs  1.1 K   0   0

63.20
+2.25 (3.69%)
NSE: 09 Sep 03:31 PM

Price Summary

Today's High

₹ 63.2

Today's Low

₹ 61

52 Week High

₹ 82.95

52 Week Low

₹ 57.4

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

70.25 Cr.

Enterprise Value

83.64 Cr.

No. of Shares

1.11 Cr.

P/E

10.34

P/B

1.56

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  40.52

CASH

0.09 Cr.

DEBT

13.48 Cr.

Promoter Holding

73.51 %

EPS (TTM)

₹  6.11

Sales Growth

0%

ROE

73.21 %

ROCE

36.83%

Profit Growth

0 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 YearNA

Profit Growth

1 YearNA
3 YearNA
5 YearNA

ROE%

1 Year73.21%

ROCE %

1 Year36.83%

Debt/Equity

2.5471

Price to Cash Flow

-18.21

Interest Cover Ratio

5.9937

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 73.51 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has a high promoter holding of 73.51%.

 Limitations

  • The company has shown a poor profit growth of 0% for the Past 3 years.
  • The company has shown a poor revenue growth of 0% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of 0% over the past 3 years
  • Company has negative cash flow from operations of -3.8569.
  • The company has a low EBITDA margin of 0% over the past 5 years.

Quarterly Result (All Figures in Cr.)

 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2024
Net Sales 33.67
Total Expenditure 26.18
Operating Profit 7.49
Other Income 0.27
Interest 1.15
Depreciation 0.85
Exceptional Items 0
Profit Before Tax 5.76
Tax 1.89
Net Profit 3.88
Adjusted EPS (Rs.) 5.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2024
Equity and Liabilities
Share Capital 4
Total Reserves 1.35
Borrowings 6.91
Other N/C liabilities 0.13
Current liabilities 14.66
Total Liabilities 27.05
Assets
Net Block 5.27
Capital WIP 0
Intangible WIP 0
Investments 0
Loans & Advances 0.13
Other N/C Assets 0.05
Current Assets 21.59
Total Assets 27.05
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2024
Profit from operations 1.87
Adjustment 2
Changes in Assets & Liabilities -7.21
Tax Paid -0.53
Operating Cash Flow -3.86
Investing Cash Flow -0.11
Financing Cash Flow 4.02
Net Cash Flow 0.06

Corporate Actions

Investors Details

PARTICULARS Jun 2025%
promoters 73.51
ankita vivek patel 0.68
hardik mukundbhai prajapa... 17.69
harshad nanubhai rathod 17.69
mayu popatlal sojitra 17.69
pooja harshad rathod 0.68
shweta sojitra 0.68
vaishaki hardik prajapati... 0.68
vivek ashokkumar patel 17.69
 No Investors Data available for this company.Report us

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit and Research reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation and Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Accretion Pharma. Stock Price Analysis and Quick Research Report. Is Accretion Pharma. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Accretion Pharma.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Accretion Pharma. has a PE ratio of 10.3420062182949 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Accretion Pharma. has ROA of 14.3285% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Accretion Pharma. has a Current ratio of 1.4721.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Accretion Pharma. has a ROE of 73.2142%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Accretion Pharma. has a Debt to Equity ratio of 2.5471 which means that the company has high proportion of debt in its capital.

  • Sales growth: Accretion Pharma. has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Accretion Pharma. for the current financial year is 22.2467117379371%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Accretion Pharma. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Accretion Pharma. is Rs 6.111. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Accretion Pharma. in Ticker for free. Also, one can get the intrinsic value of Accretion Pharma. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Accretion Pharma. FAQs

Q1. What is Accretion Pharma. share price today?
Ans: The current share price of Accretion Pharma. is Rs 63.2.

Q2. What is the market capitalisation of Accretion Pharma.?
Ans: Accretion Pharma. has a market capitalisation of Rs 70.25312 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Accretion Pharma.?
Ans: The PE ratio of Accretion Pharma. is 10.3420062182949 and the P/B ratio of Accretion Pharma. is 1.55973899051323, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Accretion Pharma. share?
Ans: The 52-week high share price of Accretion Pharma. is Rs 82.95, and the 52-week low share price of Accretion Pharma. is Rs 57.4.

Q5. Does Accretion Pharma. pay dividends?
Ans: Currently, Accretion Pharma. does not pay dividends. Dividend yield of Accretion Pharma. is around 0%.

Q6. What are the face value and book value of Accretion Pharma. shares?
Ans: The face value of Accretion Pharma. shares is Rs 10, while the book value per share of Accretion Pharma. is around Rs 40.5196. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Accretion Pharma.?
Ans: Accretion Pharma. has a total debt of Rs 13.4822 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Accretion Pharma.?
Ans: The ROE of Accretion Pharma. is 73.2142% and ROCE of Accretion Pharma. is 36.833%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Accretion Pharma. a good buy for the long term?
Ans: The Accretion Pharma. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Accretion Pharma. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Accretion Pharma. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Accretion Pharma.’s financials?
Ans: You can review Accretion Pharma.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Accretion Pharma.
X